Abstract 244P
Background
Non clear cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumors; usually treated with immunotherapy (IO) and or tyrosine kinase inhibitors (TKI). Prospective large-scale data from Asia specific countries is limited. We aimed to present the demographic profile and treatment outcome of nccRCC patients from single centre in India.
Methods
This is a retrospective study on patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata-West Bengal from 2012-2022. Demographic profiles, histologic subtypes, treatment details, response to therapy (by RECIST v1.1) and survival status were captured from electronic medical records of hospitals up till March 2023. Progression free survival (PFS) and Overall survival (OS) were estimated using Kaplan Meier method.
Results
A total of 89 patients were screened;24 excluded due to inadequate records. 65 patients were included in analysis, with a median age at diagnosis of 59 years (range 20-84). Histologic subtypes comprised 43% (n=28) papillary, 31%(n=20) clear cell with mixed histology, 3%(2) sarcomatoid & 23%(15) others including chromophobe, oncocytoma. The most common site of metastasis was lung 62% (n=40).15% presented with haematuria and 62%(n=40) underwent cytoreductive nephrectomy. Majority received pazopanib 46% (n=30) then chemotherapy 20% (n=13) including bevacizumab plus erlotinib, sunitinib 15%(10), cabozantinib 14%(9). Only 3(5%) received IO plus TKI combination. The best response was CR in 1.5%, PR 20%, SD 51% & PD 23% as per RECIST v1.1. Total 17 (26%) patients required dose reduction & interruption due to adverse effects & 33% received second-line therapy with nivolumab,axitinib & everolimus were commonly used. After a median follow up of 44 months; median PFS was 13 months (95%CI 7.2-18.9) & median OS was 17 months (95%CI 12.1-22.1). Regression analysis identified better outcome for PFS & OS with sarcomatoid subtype & those underwent prior nephrectomy.
Conclusions
The overall response and survival was quite impressive in comparison with published data; despite limited number of cases treated with IO due to its cost.This study also highlighted better survival with sarcomatoid subtype and prior nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract